The metabolic half of the workup runs on a schedule

What the evidence says

The condition is metabolic as well as reproductive, and the 2023 international guideline says the metabolic half gets checked on a schedule: glucose at diagnosis and then every one to three years depending on other risk factors, blood pressure every year, and a lipid profile at diagnosis. That is because the risk of type 2 diabetes is higher regardless of age and weight.

The preferred glucose test is a 75-g oral glucose tolerance test, with fasting glucose or HbA1c as less accurate options when that test cannot be done. The lipid profile covers total cholesterol, LDL, HDL and triglycerides, and is repeated depending on the results and other risk factors. One more risk, stated plainly: the guideline names long-standing untreated absent periods as a risk factor for endometrial hyperplasia and cancer. The overall chance of endometrial cancer stays low, so routine screening is not recommended. Instead, prolonged absent periods deserve a clinician's plan: the guideline names regulating cycles, including with a regular progestogen, as a way to prevent it.

What this does not show

A screening list is not a risk statement about you. 'Higher risk' compares populations, and nothing here estimates your risk of anything. Which tests, how often, and what your results mean are your clinician's calls, made with your history: the guideline sets the floor, your plan is individual. The endometrial risk is a reason to be seen, never a reason to panic: the overall chance stays low, and the risk factor the guideline names is long-standing untreated absence of periods, not a single late cycle.

Sources, as Neta holds them

1. Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023;108(10):2447-69. doi:10.1210/clinem/dgad463

   Guideline synthesis